Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)

BACKGROUND:Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and GABA-A antibodies were found more prevalent in people with psychosis than in he...

Full description

Bibliographic Details
Main Authors: Lennox, B, Yeeles, K, Jones, P, Zandi, M, Joyce, E, Yu, L, Tomei, G, Pollard, R, Vincent, S, Shimazaki, M, Cairns, I, Dowling, F, Kabir, T, Barnes, T, Lingford Hughes, A, Hosseini, A, Harrower, T, Buckley, C, Coles, A
Format: Journal article
Language:English
Published: BioMed Central 2019

Similar Items